Medtronic Tops Estimates as Strong Demand for Heart Devices and Glucose Monitors Lifts Results
Medtronic reported third-quarter results that exceeded analyst expectations, driven by robust sales of heart therapies including pulsed field ablation systems and transcatheter aortic valve replacement devices, and continued uptake of continuous glucose monitoring. The company left its fiscal 2026 adjusted EPS forecast unchanged at $5.62 to $5.66.